WuXi XDC announces mechanical completion of Singapore site

The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025

WuXi XDC and LigaChem Biosciences expands MoU to accelerate ADC development

WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs

WuXi XDC partners with IntoCell to accelerate ADC discovery and development

IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate

WuXi XDC and Boostimmune sign MoU for integrated services

Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform

GeneQuantum and WuXi XDC enter into strategic cooperation to empower innovative bioconjugates development

WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates

AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing

DualityBio collaborates with BioNTech to accelerate development of differentiated antibody-drug conjugate therapeutics

WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.